ما هو علاج لمفوما بوركيت خط أول؟

References

• In 1996, Magrath and colleagues, at the National Cancer Institute (NCI), published their experience with cyclophosphamide, doxorubicin, vincristine, methotrexate, ifosfamide, cytarabine, and etoposide (CODOX-M/IVAC).
• The regimen includes both high-dose, systemically administered and intrathecal methotrexate and cytarabine to treat and prevent disease recurrence in the CNS.
• Given the improvement in outcomes with its use in aggressive lymphoma, rituximab has been incorporated broadly into BL regimens.
• Low-risk patients received 3 cycles of dose-adjusted R-EPOCH without CNS prophylaxis, and high-risk patients received 6 cycles with intrathecal CNS prophylaxis or extended intrathecal treatment if the leptomeninges were involved.
• Patients were treated with 2 cycles beyond complete remission (6 to 8 total) with the exception of HIV patients who received 1 cycle beyond complete response (3 to 6 total) with 2 doses of rituximab administered with each cycle.